Table 6.
Distribution of Deaths - NSABP STAR Trial (P-2)
| Cause of death | Deaths, n |
|
|---|---|---|
| Tamoxifen | Raloxifene | |
| Cancer | 101 | 86 |
| Bladder | 1 | 3 |
| Bone, articular cartilage and connective tissue | 1 | 1 |
| Brain | 6 | 4 |
| Breast | 11 | 4 |
| Colon | 4 | 3 |
| Endocrine gland | 0 | 1 |
| Gallbladder | 2 | 1 |
| Kidney | 1 | 1 |
| Liver | 7 | 1 |
| Lung | 25 | 28 |
| Lymphatic/hematopoietic | 12 | 11 |
| Oral | 2 | 1 |
| Ovary | 8 | 7 |
| Pancreas | 7 | 5 |
| Peritoneum | 2 | 0 |
| Skin | 2 | 0 |
| Spleen | 0 | 1 |
| Stomach | 2 | 1 |
| Thyroid | 1 | 0 |
| Uterus | 2 | 2 |
| Other, uncertain, and unspecified sites | 5 | 11 |
| Circulatory/vascular disease | 42 | 42 |
| Aortic | 1 | 2 |
| Atherosclerosis | 0 | 1 |
| Cerebrovascular disease, unspecified | 1 | 0 |
| Hypertensive disease | 1 | 4 |
| Ischemic heart disease | 13 | 8 |
| Other heart disease | 9 | 14 |
| Peripheral vascular disease, unspecified | 0 | 1 |
| Polyarteritis nodosa | 0 | 1 |
| Pulmonary embolism | 3 | 2 |
| Primary pulmonary hypertension | 1 | 0 |
| Stroke | 13 | 9 |
| Other | 93 | 74 |
| Accident, auto | 3 | 4 |
| Accident, fire | 1 | 0 |
| Alcohol dependence syndrome | 1 | 1 |
| Asphyxiation and strangulation | 1 | 0 |
| Complications of surgery | 0 | 1 |
| Dementia | 0 | 1 |
| Diabetes | 1 | 3 |
| Disorders of metabolism | 1 | 0 |
| Emphysema | 1 | 0 |
| Injury, intracranial | 2 | 2 |
| Injury, other | 1 | 0 |
| Interferon toxicity | 0 | 1 |
| Intestinal infectious disease | 0 | 1 |
| Other conditions of the blood | 0 | 2 |
| Other conditions of the brain/neurological system | 7 | 3 |
| Other diseases of the digestive system | 7 | 6 |
| Other Diseases of the urinary system | 2 | 1 |
| Other respiratory disease | 13 | 7 |
| Pneumonia | 2 | 4 |
| Poisoning | 2 | 0 |
| Septicemia | 4 | 3 |
| Skin infections | 0 | 1 |
| Symptoms, signs, and ill-defined conditions | 2 | 3 |
| Unknown | 42 | 30 |
| Total deaths (rate per 1,000) | 236 (3.81) | 202 (3.22) |
| Risk ratio (95% CI) | 0.84 (0.70–1.02) | |
Abbreviations: CI, confidence interval; NSABP STAR, National Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene